Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis

References

• Considering the impact of COVID-19 on children [Internet]. [accessed 2022 Jun 19]. https://www.who.int/europe/activities/considering-the-impact-of-covid-19-on-children
   Google Scholar
• COVID-19 and children [Internet]. UNICEF DATA. [accessed 2022 Jun 19]. https://data.unicef.org/covid-19-and-children/
   Google Scholar
• Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, Murray B, Kläser K, Kerfoot E, Chen L, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021;5(10):1–17. doi:10.1016/S2352-4642(21)00198-X.
   PubMedGoogle Scholar
• Cloete J, Kruger A, Masha M, du Plessis NM, Mawela D, Tshukudu M, Manyane T, Komane L, Venter M, Jassat W, et al. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study. Lancet Child Adolesc Health. 2022;6(5):294–302. doi:10.1016/S2352-4642(22)00027-X.
   PubMedGoogle Scholar
• Sacco K, Castagnoli R, Vakkilainen S, Liu C, Delmonte OM, Oguz C, Kaplan IM, Alehashemi S, Burbelo PD, Bhuyan F, et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nat Med. 2022;28(5):1050–62. doi:10.1038/s41591-022-01724-3.
   PubMed Web of Science ®Google Scholar
• Stephenson T, Pereira SMP, Shafran R, de Stavola BL, Rojas N, McOwat K, Simmons R, Zavala M, O’Mahoney L, Chalder T, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. Lancet Child Adolesc Health. 2022;6(4):230–39. doi:10.1016/S2352-4642(22)00022-0.
   PubMedGoogle Scholar
• Nachega JB, Sam-Agudu NA, Machekano RN, Rabie H, van der Zalm MM, Redfern A, Dramowski A, O’Connell N, Pipo MT, Tshilanda MB, et al. Assessment of clinical outcomes among children and adolescents hospitalized with COVID-19 in 6 sub-saharan African countries. JAMA Pediatr. 2022;176(3):e216436. doi:10.1001/jamapediatrics.2021.6436.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, et al. Bnt162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–89. doi:10.1038/s41586-021-03275-y.
   PubMed Web of Science ®Google Scholar
• Frenck RWJ, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. doi:10.1056/NEJMoa2107456.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira EDJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–73. doi:10.1056/NEJMoa2110345.
   PubMed Web of Science ®Google Scholar
• Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual for the revised WHO classification , 2nd ed., 2019 update [Internet]. [accessed 2022 Sep 28]. https://www.who.int/publications-detail-redirect/9789241516990
   Google Scholar
• SYSTEMATIC USE OF CAUSALITY ASSESSMENT IN AEFI SURVEILLANCE: a 2013-2016 pilot study in puglia [Internet]. [accessed 2022 Sep 28]. http://www.embj.org/embj/causality-assessment-aefi-surveillance/
   Google Scholar
• Lee CW, Sa S, Hong M, Kim J, Shim SR, Han HW. Adverse events and safety profile of the COVID-19 vaccines in adolescents: safety monitoring for adverse events using real-world data. Vaccines. 2022;10(5):744. doi:10.3390/vaccines10050744.
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–28. doi:10.1038/s41591-020-1124-9.
   PubMed Web of Science ®Google Scholar
• Solís Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, Syunyaev G, Malik AA, Aboutajdine S, Adeojo O, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27(8):1385–94. doi:10.1038/s41591-021-01454-y.
   PubMed Web of Science ®Google Scholar
• Harapan H, Anwar S, Yufika A, Sharun K, Gachabayov M, Fahriani M, Husnah M, Raad R, Abdalla RY, Adam RY, et al. Vaccine hesitancy among communities in ten countries in Asia, Africa, and South America during the COVID-19 pandemic. Pathog Glob Health. 2022;116(4):236–43. doi:10.1080/20477724.2021.2011580.
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Alobwede SM, de Marie C, Katoto P, Kidzeru EB, Lumngwena EN, Cooper S, Goliath R, Jackson A, Shey MS. Cross-cultural adaptation and validation of the 5C scale to identify factors associated with COVID-19 and influenza vaccine hesitancy among healthcare workers in cape town, South Africa – a protocol. Expert Rev Vaccines. 2022;11:1–11. doi:10.12688/f1000research.123332.1.
   Google Scholar
• Dinga JN, Sinda LK, Titanji VPK. Assessment of vaccine hesitancy to a COVID-19 vaccine in Cameroonian adults and its global implication. Vaccines (Basel). 2021;9(2):175. doi:10.3390/vaccines9020175.
   PubMed Web of Science ®Google Scholar
• Temsah M-H, Alhuzaimi AN, Aljamaan F, Bahkali F, Al-Eyadhy A, Alrabiaah A, Alhaboob A, Bashiri FA, Alshaer A, Temsah O, et al. Parental attitudes and hesitancy about COVID-19 vs. routine childhood vaccinations: a national survey. Front Public Health. 2021;9:752323. doi:10.3389/fpubh.2021.752323.
   PubMed Web of Science ®Google Scholar
• Goldman RD, Krupik D, Ali S, Mater A, Hall JE, Bone JN, Thompson GC, Yen K, Griffiths MA, Klein A, et al. Caregiver willingness to vaccinate their children against COVID-19 after adult vaccine approval. Int J Environ Res Public Health. 2021;18(19):10224. doi:10.3390/ijerph181910224.
   PubMed Web of Science ®Google Scholar
• Chen F, He Y, Shi Y. Parents’ and guardians’ willingness to vaccinate their children against COVID-19: a systematic review and meta-analysis. Vaccines (Basel). 2022;10(2):179. doi:10.3390/vaccines10020179.
   PubMed Web of Science ®Google Scholar
• Ten health issues WHO will tackle this year [Internet]. [accessed 2021 Sep 27]. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
   Google Scholar
• Katoto PDMC, Parker S, Coulson N, Pillay N, Cooper S, Jaca A, Mavundza E, Houston G, Groenewald C, Essack Z, et al. Predictors of COVID-19 vaccine hesitancy in South African local communities: the VaxScenes study. Vaccines. 2022;10(3):353. doi:10.3390/vaccines10030353.
   Web of Science ®Google Scholar
• Karafillakis E, Simas C, Jarrett C, Verger P, Peretti-Watel P, Dib F, De Angelis S, Takacs J, Ali KA, Pastore Celentano L, et al. HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum Vaccin Immunother. 2019;15(7–8):1615–27. doi:10.1080/21645515.2018.1564436.
   PubMed Web of Science ®Google Scholar
• Wiyeh AB, Cooper S, Nnaji CA, Wiysonge CS. Vaccine hesitancy ‘outbreaks’: using epidemiological modeling of the spread of ideas to understand the effects of vaccine related events on vaccine hesitancy. Expert Rev Vaccines. 2018;17(12):1063–70. doi:10.1080/14760584.2018.1549994.
   PubMed Web of Science ®Google Scholar
• Wagner AL, Huang Z, Ren J, Laffoon M, Ji M, Pinckney LC, Sun X, Prosser LA, Boulton ML, Zikmund-Fisher BJ. Vaccine hesitancy and concerns about vaccine safety and effectiveness in Shanghai, China. Am J Prev Med. 2021;60(1):S77–86. doi:10.1016/j.amepre.2020.09.003.
   PubMed Web of Science ®Google Scholar
• Hou Z, Tong Y, Du F, Lu L, Zhao S, Yu K, Piatek SJ, Larson HJ, Lin L. Assessing COVID-19 vaccine hesitancy, confidence, and public engagement: a global social listening study. J Med Internet Res. 2021;23(6):e27632. doi:10.2196/27632.
   PubMed Web of Science ®Google Scholar
• Tram KH, Saeed S, Bradley C, Fox B, Eshun-Wilson I, Mody A, Geng ED. Dissent, and distrust: understanding distinct drivers of coronavirus disease 2019 vaccine hesitancy in the United States. Clin Infect Dis [Internet]; 2021 Sep 28;74(8):1429–41. doi:10.1093/cid/ciab633.
   Web of Science ®Google Scholar
• Wiyeh AB, Cooper S, Jaca A, Mavundza E, Ndwandwe D, Wiysonge CS. Social media and HPV vaccination: unsolicited public comments on a facebook post by the western cape department of health provide insights into determinants of vaccine hesitancy in South Africa. Vaccine. 2019;37(43):6317–23. doi:10.1016/j.vaccine.2019.09.019.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. doi:10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rücker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10(3):476–83. doi:10.1002/jrsm.1348.
   PubMed Web of Science ®Google Scholar
• Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–72. doi:10.1002/(SICI)1097-0258(19980430)17:8<857:AID-SIM777>3.0.CO;2-E.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. doi:10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. doi:10.1136/bmj.315.7109.629.
   PubMed Web of Science ®Google Scholar
• Alamer E, Alhazmi A, Qasir NA, Alamer R, Areeshi H, Gohal G, Qadri M, Hashem AM, Algaissi A. Side effects of COVID-19 Pfizer-BioNtech mRNA vaccine in children aged 12–18 years in Saudi Arabia. Vaccines (Basel). 2021;9(11):1297. doi:10.3390/vaccines9111297.
   PubMed Web of Science ®Google Scholar
• Hause AM. COVID-19 vaccine safety in children aged 5–11 years — United States , November 3–December 19 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [accessed 2022 Feb 7]; 70. https://www.cdc.gov/mmwr/volumes/70/wr/mm705152a1.htm
   Google Scholar
• Hause AM. Safety monitoring of COVID-19 vaccine booster doses among persons aged 12–17 Years — United States, December 9, 2021–February 20, 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [accessed 2022 Mar 10]; 71. http://www.cdc.gov/mmwr/volumes/71/wr/mm7109e2.htm
   Google Scholar
• Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, Omori K, Akita T, Shigemoto N, Tanaka J, et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J Infect Chemother. 2022;28(4):576–81. doi:10.1016/j.jiac.2021.12.034.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390–99. doi:10.1001/jama.2021.15072.
   PubMed Web of Science ®Google Scholar
• Chan EWW, Leung MTY, Lau LKW, Leung J, Lum D, Wong R-M, Li X, Chui CSL, Wan EYF, Wong CKH, et al. Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNtech) messenger RNA COVID-19 vaccine: a prospective cohort study. Int J Infect Dis. 2022;116:47–50. doi:10.1016/j.ijid.2021.12.354.
   PubMed Web of Science ®Google Scholar
• June Choe Y, Yi S, Hwang I, Kim J, Park Y-J, Cho E, Jo M, Lee H, Hwa Choi E. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. Vaccine. 2022;40(5):691–94. doi:10.1016/j.vaccine.2021.12.044.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Chua GT, Chan EWW, Huang L, Kwan MYW, Ma T, Qin X, Chui CSL, Li X, Wan EYF, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect. 2022;11(1):885–93. doi:10.1080/22221751.2022.2050952.
   PubMed Web of Science ®Google Scholar
• Tafuri S, Fortunato F, Gallone MS, Stefanizzi P, Calabrese G, Boccalini S, Martinelli D, Prato R. Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy). Vaccine. 2018;36(8):1072–77. doi:10.1016/j.vaccine.2018.01.018.
   PubMed Web of Science ®Google Scholar
• Varallo FR, de Oliveira Paim Guimarães S, Abjaude SAR, de Carvalho Mastroianni P. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP. 2014;48(4):739–47. doi:10.1590/S0080-623420140000400023.
   PubMed Web of Science ®Google Scholar
• VAERS. Guide to Interpreting VAERS Data [Internet]. [accessed 2022 Sep 28]. https://vaers.hhs.gov/data/dataguide.html
   Google Scholar
• Amanzio M, Mitsikostas DD, Giovannelli F, Bartoli M, Cipriani GE, Brown WA. Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: a systematic review. Lancet Reg Health Eur. 2022;12:100253. doi:10.1016/j.lanepe.2021.100253.
   PubMedGoogle Scholar
• Wan EYF, Chui CSL, Lai FTT, Chan EWY, Li X, Yan VKC, Gao L, Yu Q, Lam ICH, Chun RKC, et al. Bell’s palsy following vaccination with mRNA (Bnt162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2022;22(1):64–72. doi:10.1016/S1473-3099(21)00451-5.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Ozaki A, Bhandari D, Sawano T, Sah R, Tanimoto T. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data. J Travel Med. 2021;28(7):taab090. doi:10.1093/jtm/taab090.
   PubMed Web of Science ®Google Scholar
• Sobczak M, Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clinical and Molecular Allergy. 2022;20(1):1. doi:10.1186/s12948-022-00167-y.
   PubMedGoogle Scholar
• Inoue S, Igarashi A, Morikane K, Hachiya O, Watanabe M, Kakehata S, Sato S, Ueno Y. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy. Respir Investig. 2022;60(2):248–55. doi:10.1016/j.resinv.2021.11.007.
   PubMed Web of Science ®Google Scholar
• Shavit R, Maoz-Segal R, Iancovici-Kidon M, Offengenden I, Haj Yahia S, Machnes Maayan D, Lifshitz-Tunitsky Y, Niznik S, Frizinsky S, Deutch M, et al. Prevalence of allergic reactions after Pfizer-BioNtech COVID-19 vaccination among adults with high allergy risk. JAMA Netw Open. 2021;4(8):e2122255. doi:10.1001/jamanetworkopen.2021.22255.
   PubMed Web of Science ®Google Scholar
• Block JP. Cardiac complications after SARS-CoV-2 Infection and mRNA COVID-19 vaccination — PCORnet, United States, January 2021–January 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [accessed 2022 Jun 20] 71. http://www.cdc.gov/mmwr/volumes/71/wr/mm7114e1.htm
   Google Scholar
• Top KA, Macartney K, Bettinger JA, Tan B, Blyth CC, Marshall HS, Vaudry W, Halperin SA, McIntyre P. Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia. Euro Surveill. 2020;25(25):1900562. doi:10.2807/1560-7917.ES.2020.25.25.1900562.
   PubMedGoogle Scholar
• Centre UM. About VigiBase [Internet]. [accessed 2022 Jun 20]. https://who-umc.org/vigibase/
   Google Scholar